Join our daily newsletter At The Bell to receive exclusive market insights
Biotron (ASX:BIT) has been forced to explain its position to ASX Compliance after being queried by the regulator over why it didn’t classify as ‘price sensitive’ an announcement foreshadowing potential bankruptcy.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The answer? Human error. Literally – the company ticked the wrong box.
“The announcement was considered by the company to be market sensitive… Unfortunately, during lodgement of the announcement, the wrong box… was pressed. This was a human error,” Biotron wrote on Tuesday.
Checkmate, regulators.
As for additional concerns that the company didn’t make price sensitive a share purchase plan announcement, there too the regulator is worrying unduly – because Biotron made it clear it’s since changed that to a rights issue.
(“As a result this question is no longer relevant,” it added, despite the fact it still needs $500,000 regardless of how it raises it.)
The last time Biotron undertook a capital raising was back in November 2022 when it raised funds to undertake COVID clinical trials and complete two second stage HIV-2 studies.
Of course, many biotech companies got left stranded by the tide of COVID, which really only lasted three years from a lockdowns point of view.
The healthcare nanocap, which has long been trying to focus its efforts on a range of diseases, has been one that’s missed out on the biotech rally visible from late 2024 to 2025.
More market news
Pushing in: Ukraine’s minerals are in Trump’s sights. What does this really mean?
Tough trim: Why rate cuts are bad news for the Australian economy
This prompted Biotron to swing back to its financial position.
“There was always a possibility that additional capital would be required to fund the next stage of development/activities now that the Phase 2 trials are completed, as was disclosed at the time, and which is standard in the industry and with a R&D company that does not have revenues,” Biotron wrote.
For now, its rights issue is underwritten for $750,000 by Mahe Capital.
BIT last traded at 0.4cps.
Join the discussion: See what HotCopper users are saying about Biotron and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
